drugset / Trial / NCT01001143
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective is to determine the safety and tolerability of combination decitabine and bexarotene during four cycles of therapy.
Timeline
- Start
- 2010-05
- Primary completion
- 2013-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 100 mg/m2 | Oral |
| Subject | Bexarotene | Small molecule | 200 mg/m2 | Oral |
| Subject | Bexarotene | Small molecule | 300 mg/m2 | Oral |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |